Swiss National Bank trimmed its stake in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 4.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,251,060 shares of the specialty pharmaceutical company’s stock after selling 61,600 shares during the period. Swiss National Bank owned 0.36% of Valeant Pharmaceuticals International worth $21,748,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of VRX. Gruss & Co. Inc. purchased a new position in Valeant Pharmaceuticals International during the first quarter valued at $104,000. Harbor Advisors LLC purchased a new position in Valeant Pharmaceuticals International during the first quarter valued at $110,000. WMS Partners LLC purchased a new position in Valeant Pharmaceuticals International during the first quarter valued at $116,000. PNC Financial Services Group Inc. grew its stake in Valeant Pharmaceuticals International by 33.7% during the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after acquiring an additional 2,763 shares in the last quarter. Finally, Baird Financial Group Inc. purchased a new position in Valeant Pharmaceuticals International during the first quarter valued at $127,000. 50.49% of the stock is owned by institutional investors.

In other news, Director Schutter Richard U. De bought 10,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Monday, August 21st. The shares were purchased at an average price of $14.33 per share, with a total value of $143,300.00. Following the completion of the acquisition, the director now directly owns 77,479 shares in the company, valued at $1,110,274.07. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.87% of the stock is owned by company insiders.

A number of equities analysts have commented on the stock. BMO Capital Markets reissued a “hold” rating and issued a $15.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Thursday, July 27th. Zacks Investment Research raised shares of Valeant Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Thursday, July 27th. Deutsche Bank AG set a $19.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research note on Monday, July 17th. J P Morgan Chase & Co set a $10.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research note on Monday, July 17th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $35.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Friday, June 30th. Five research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $17.67.

Valeant Pharmaceuticals International, Inc. (VRX) opened at 13.61 on Monday. The stock’s market cap is $4.74 billion. The stock has a 50 day moving average of $14.87 and a 200-day moving average of $13.27. Valeant Pharmaceuticals International, Inc. has a 12 month low of $8.31 and a 12 month high of $29.57.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.08. The firm had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm’s revenue was down 7.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.88) earnings per share. On average, equities analysts forecast that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/11/valeant-pharmaceuticals-international-inc-vrx-shares-sold-by-swiss-national-bank.html.

Valeant Pharmaceuticals International Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.